NCT06537128

Brief Summary

Anxiety is very common in autistic youth. Cognitive behavioral therapy (CBT) is the recommended treatment for both autistic and typically-developing (TD) youth with anxiety, yet most families cannot access CBT due to cost, practicalities of attending in-person treatment sessions, and a shortage of trained providers, especially in rural areas. The goal of this project is to increase access to care for families of autistic adolescents with anxiety through an internet-based treatment model.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
139

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Nov 2024

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 31, 2024

Completed
5 days until next milestone

First Posted

Study publicly available on registry

August 5, 2024

Completed
3 months until next milestone

Study Start

First participant enrolled

November 1, 2024

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2026

Completed
Last Updated

July 23, 2025

Status Verified

July 1, 2025

Enrollment Period

1.4 years

First QC Date

July 31, 2024

Last Update Submit

July 18, 2025

Conditions

Keywords

Cognitive Behavioral TherapyAdolescentsAutismAnxiety

Outcome Measures

Primary Outcomes (1)

  • Pediatric Anxiety Rating Scale modified for ASD (PARS-ASD)

    Clinician-rated child anxiety severity throughout the past week. Each item is scored on a 0 to 5 scale (higher scores correspond to greater severity), yielding a total between 0 and 35. This measure has been modified for autistic youth

    Baseline (before treatment), during treatment (on average 6 weeks), post-treatment (on average 12 weeks), 1 month follow up

Secondary Outcomes (2)

  • Clinical Global Impression-Improvement (CGI-I)

    during treatment (on average 6 weeks), post-treatment (on average 12 weeks), 1 month follow up

  • Screen for Child Anxiety Related Disorders (SCARED)

    Baseline (before treatment), post-treatment (on average 12 weeks), 1 month follow up

Study Arms (2)

LUNA-Adolescent

ACTIVE COMPARATOR

Dyads in the Learning to Understand and Navigate Anxiety-Adolescent (LUNA-Adolescent) group will receive internet-based cognitive behavioral therapy (LUNA-Adolescent), which includes 12 weekly treatment modules, 6 bi-weekly, 30-minutes telehealth visits, and email check-ins.

Behavioral: LUNA-Adolescent

Treatment as Usual

PLACEBO COMPARATOR

Dyads in the standard-care cognitive behavioral therapy (CBT) group will receive 12 weekly sessions of transdiagnostic CBT for anxiety in autistic youth.

Behavioral: Treatment as Usual

Interventions

LUNA-AdolescentBEHAVIORAL

Learning to Understand and Navigate Anxiety-Adolescent (LUNA-Adolescent) includes parent-led, internet-based cognitive behavioral therapy (CBT) for anxiety among autistic youth.

Also known as: Internet-based Cognitive Behavioral Therapy
LUNA-Adolescent

Treatment as Usual includes 12 weekly sessions of transdiagnostic cognitive behavioral therapy (CBT) for anxiety in autistic youth.

Treatment as Usual

Eligibility Criteria

Age11 Years - 17 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • The child is between the age of 11-17 years old at enrollment.
  • The child is diagnosed with autism using a validated assessment (e.g., Autism Diagnostic Observation Schedule-Second Edition (ADOS-2), Childhood Autism Rating Scale-Second Edition (CARS-2), etc.).
  • The child has current, clinically significant anxiety and/or OCD as indicated by a clinician-administered standardized assessment (e.g. Mini-International Neuropsychiatric Interview for Children and Adolescents (MINI-KID) and Pediatric Rating Anxiety Scale modified for autism (PARS-ASD)).
  • Anxiety disorder is the child's primary/co-primary psychiatric diagnosis, and if secondary psychopathology is present, it will not interfere with treatment.
  • One parent/guardian over the age of 18 is able and willing to participate in assessment and treatment (e.g. has sufficient English/Spanish fluency, the decisional capacity to participate, and can commit to treatment duration).
  • The child is able to communicate verbally.
  • Participants are located in Texas.
  • The participant has an IQ above 69, based on the Kaufman Brief Intelligence Test-Second Edition (KBIT-2), another valid test or clinician judgement (e.g., a previous assessment conducted, and report shared with study team)

You may not qualify if:

  • The child has a diagnosis of a lifetime psychotic disorder and/or conduct disorder.
  • The child has significant, current suicidal/homicidal ideation and/or self-injury requiring medical intervention.
  • The child has limited verbal communication abilities (e.g., no independent verbal communication),
  • The child is receiving concurrent psychotherapy (including certain forms of social skills training, or behavioral interventions that target anxiety such as applied behavioral analysis).
  • The child has initiated new antidepressant medication within 12-weeks of assessment (4-weeks for stimulants/benzodiazepines/antipsychotics) or during therapy.
  • The child has changed psychotropic medication dosage within 4-weeks of assessment (2-weeks for stimulants/benzodiazepines/antipsychotics) or during therapy.
  • The child requires a higher level than can be provided through the study (e.g., significant, current suicidal ideation)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Baylor College of Medicine

Houston, Texas, 77030, United States

RECRUITING

MeSH Terms

Conditions

Autism Spectrum DisorderAutistic DisorderAnxiety DisordersGeneralized Anxiety DisorderPhobia, Social

Interventions

Therapeutics

Condition Hierarchy (Ancestors)

Child Development Disorders, PervasiveNeurodevelopmental DisordersMental DisordersPhobic Disorders

Study Officials

  • Eric Storch, PhD

    Baylor College of Medicine

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Callie Murphy, B.A.

CONTACT

Jolie Held, BA

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Masking Details
Independent evaluators will be blind to which group participants are randomized into.
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Randomized assignment to one of two conditions
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

July 31, 2024

First Posted

August 5, 2024

Study Start

November 1, 2024

Primary Completion

April 1, 2026

Study Completion

April 1, 2026

Last Updated

July 23, 2025

Record last verified: 2025-07

Data Sharing

IPD Sharing
Will not share

Locations